Fluorescent Ligands in Fluorescence Polarization Assays: A Game-Changer for GPCR Drug Discovery
The development of new therapeutics depends on the ability to identify compounds that interact with specific molecular targets involved in disease pathways. Target-based screening has become a fundamental approach in drug discovery, focusing on assessing interactions between small molecules and well-defined biological targets such as G-protein-coupled receptors (GPCRs). This method enables the systematic evaluation of potential drug candidates by measuring their binding affinity, kinetics, and selectivity.
To efficiently screen large libraries of compounds, high-throughput screening (HTS) provides rapid and scalable assessment of molecular interactions. Among the fluorescence-based techniques used in HTS, fluorescence polarization (FP) has proven to be a particularly effective approach for GPCR drug discovery. By employing fluorescent ligands, fluorescence polarization binding assays allow for real-time detection of receptor-ligand interactions.
How Fluorescence Polarization Assays Work: Principles and Applications in GPCR Research
Fluorescence polarization assays work on the principle that the polarization of a fluorescently labeled molecule decreases as its molecular rotation speed increases. Low molecular weight molecules rotate quickly, which causes the emitted fluorescence to be scattered in different directions (depolarized). However, when the fluorescent molecule binds to a larger target, such as a GPCR, its movement slows down, and the emitted fluorescence remains more aligned (polarized) (Figure 1). This change in polarization makes it possible to measure binding interactions between molecules in real-time, without the need for additional separation steps.
Figure 1. Mechanism of fluorescence polarization. Adapted from: Zhang Y, Tang H, Chen W, Zhang J. Nanomaterials Used in Fluorescence Polarization Based Biosensors. Int J Mol Sci. 2022 Aug 3;23(15):8625.
Fluorescence polarization assay is most effective when studying interactions between a large protein and a small ligand because the difference in molecular size leads to a clear change in rotational speed and polarization signal.
Fluorescence polarization assays have become particularly relevant in GPCR drug discovery. Fluorescent-labeled GPCR agonists or antagonists can be employed in FP in competitive binding assays. The results are obtained using specialized multimode plate readers that can measure the degree of fluorescence polarization. These instruments excite the fluorescently labeled ligand with polarized light and then detect the emitted light to determine changes in polarization, which indicate binding interactions.
Optimizing GPCR Drug Discovery with Fluorescence Polarization: Key Advantages and Future Perspectives
Fluorescence polarization assays present several advantages:
- They are convenient and easy to manipulate. Fluorescence polarization assays are a preferable choice over GPCR radioligands for determining binding affinities. They are accessible and do not require complex equipment for analysis, since plate readers are available in regular laboratories.
Miranda-Pastoriza et al.have demonstrated that both methods provided similar binding affinity values for A3AR ligands, with FP assays using CELT-228 hA3 adenosine receptor fluorescent antagonistyielding slightly higher but not statistically significant Ki values, as shown in Table 1. These findings support the validity of fluorescence-based screening methods as a reliable alternative to classical radioligand binding assays. FP assays offer the advantage of being non-radioactive, faster, and more adaptable to high-throughput screening while maintaining similar accuracy and sensitivity.
Table 1. Comparison of hA3 binding affinities or percentage of displacement at 1 µM measured for different compounds in human cell lines. hA₁, hA₂A, hA₂B, and hA₃ (radioligand assays): Displacement of specific radiolabeled ligands in CHO, HeLa, or HEK-293 cells, expressed as Ki (nM ± SEM, n=3) or percentage displacement at 1 µM (n=2). hA₃ (fluorescence polarization assay): Displacement of CELT-228 detected by FP measurements (n=3). Reference compounds XAC, ISVY-130, and MRS 1220 were included as standard A₃AR antagonists.
- They are compatible with various sources of GPCRs, from conventional membranes to others such as baculoviruses, as demonstrated by Tahk et al. using CELT-419 dopamine D3 receptor fluorescent ligand for binding assays with fluorescence polarization.
- They are not time-sensitive, once equilibrium binding is reached, the assay remains stable for extended periods, with the only limiting factor being the stability of the protein and small molecule ligands in the assay media.
- FP does not require energy transfer between two fluorophores, unlike other fluorescence-based techniques such as Förster Resonance Energy Transfer (FRET).
Advancing Fluorescence Polarization Assays with Custom Fluorescent Ligands
Looking ahead, fluorescence polarization technology is expected to expand its role in GPCR research through the development of novel fluorescent probes and advanced imaging techniques. New generations of fluorophores with improved photostability and brightness will enhance assay sensitivity, while integration with artificial intelligence-driven data analysis will accelerate hit identification and lead optimization.
The future of fluorescence polarization assays is closely tied to fluorescent ligands. At Celtarys, we specialize in developing custom fluorescent ligands for specific research needs. We develop optimized probes with high affinity and selectivity for any target of interest in a time and cost-effective manner.
Our expertise in ligand-receptor interactions and fluorescence techniques allows us to manage every phase of the process, from the design of the new fluorescent probes to their validation as optimal tools for your assays.
Contact us to drive further advancements in GPCR drug discovery!
References
Kumar V, Chunchagatta Lakshman PK, Prasad TK, Manjunath K, Bairy S, Vasu AS, Ganavi B, Jasti S, Kamariah N. Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening. Heliyon. 2023 Dec 19;10(1):e23864. doi: 10.1016/j.heliyon.2023.e23864.
Miranda-Pastoriza D, Bernárdez R, Azuaje J, Prieto-Díaz R, Majellaro M, Tamhankar AV, Koenekoop L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán H, Sotelo E. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3 Antagonists. ACS Med Chem Lett. 2022 Jan 10;13(2):243-249. doi: 10.1021/acsmedchemlett.1c00598.
Tahk MJ, Laasfeld T, Meriste E, Brea J, Loza MI, Majellaro M, Contino M, Sotelo E, Rinken A. Fluorescence based HTS-compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells. Front Mol Biosci. 2023 Mar 16;10:1119157. doi: 10.3389/fmolb.2023.1119157.
Vinegoni C, Feruglio PF, Gryczynski I, Mazitschek R, Weissleder R. Fluorescence anisotropy imaging in drug discovery. Adv Drug Deliv Rev. 2019 Nov-Dec;151-152:262-288. doi: 10.1016/j.addr.2018.01.019.
Zhang Y, Tang H, Chen W, Zhang J. Nanomaterials Used in Fluorescence Polarization Based Biosensors. Int J Mol Sci. 2022 Aug 3;23(15):8625. doi: 10.3390/ijms23158625
